AMD

According to the companies, a social media initiative will include donation to Prevent Blindness’ Sight-Saving Fund.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Faricimab is the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.

A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

A University of California Davis study shows that small serving of the fruit increased protective pigments in the eye.

According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.

ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

CellSight researchers at the Sue Anschutz-Rodgers Eye Center were published for a discovery that could lead to early diagnosis and intervention of dry age-related macular degeneration.

Unity Biotechnology announces improvement in visual acuity sustained through 24 weeks following single dose of UBX1325 in Phase 1 study of patients with advanced vascular eye disease.

According to the company, Susvimo is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

According to 4D Molecular Therapeutics, it has received FDA Clearance of an IND Application for 4D-150, a dual-transgene intravitreal gene therapy for patients with wet AMD.

Investigators found evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks.

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

Expert panelists provide an overview of current unmet needs in wet AMD care and discuss the potential for improving clinical outcomes and treatment burden.

Key opinion leaders in ophthalmology comment on the potential role of alternative targets beyond VEGF-A including VEGF-C/VEGF-D and tyrosine kinase inhibitors.

A panel of expert ophthalmologists provides insight into emerging clinical trial data on new molecules, surgical implants, and gene therapy in wet AMD.

A panel of experts discusses nonexudative neovascular AMD and challenges associated with diagnostic imaging such as OCT-A and fluorescein angiography.

Key opinion leaders discuss factors to consider when selecting treatments in wet AMD including insurance considerations and degree of clinical response.

Panelists consider the theoretical systemic safety of anti-VEGF agents in wet AMD and discuss their role in the management of patients with risk factors.